Evidence map›Paper›PMID 37954131›Full record

ArticleInternational journal of genomics2023

Correlation between LSM1 Expression and Clinical Outcomes in Glioblastoma and Functional Mechanisms.

Changcheng Cai, Xingyu Chen, Jimin He, Chengwei Xiang, Yinggang Liu, Ke Wu, Ke Luo

Open access · goldAbstract read
In one paragraph

Article in International journal of genomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Changcheng CaiDepartment of Neurosurgery, Suining Central Hospital, Suining, 629000 Sichuan, China.
Xingyu ChenDepartment of Neurosurgery, Suining Central Hospital, Suining, 629000 Sichuan, China.
Jimin HeDepartment of Neurosurgery, Suining Central Hospital, Suining, 629000 Sichuan, China.
Chengwei XiangDepartment of Neurosurgery, Suining Central Hospital, Suining, 629000 Sichuan, China.
Yinggang LiuDepartment of Neurosurgery, Suining Central Hospital, Suining, 629000 Sichuan, China.
Ke WuDepartment of Neurosurgery, Xichang People's Hospital, Xichang, 615000 Sichuan, China.
Ke LuoDepartment of Neurosurgery, Suining Central Hospital, Suining, 629000 Sichuan, China.ORCID https://orcid.org/0009-0006-9750-082X
Suizhou Central Hospital · CNXichang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glioblastoma (GBM) is an aggressive form of brain tumor characterized by limited treatment options and a bleak prognosis. Although the role of Like-Sm 1 (LSM1), a component of the mRNA splicing machinery, has been studied in various cancers, its significance in GBM remains unclear. The purpose of this research was to investigate the expression of LSM1 and its role in driving GBM progression. Methods: We analyzed gene expression data obtained from TCGA and GTEx databases to compare the levels of LSM1 expression between GBM and normal brain tissues. To assess the impact of LSM1, we conducted experiments using U87 GBM cells, wherein we manipulated LSM1 expression through overexpression and knockdown techniques. These experiments allowed us to evaluate cellular behaviors such as proliferation and invasion. Additionally, we explored the correlation between LSM1 expression and immune cell infiltration in GBM. Results: Our analysis of TCGA and GTEx datasets revealed a significant upregulation of LSM1 expression in GBM compared to normal brain tissues. In our in vitro experiments using U87 cells, we observed that LSM1 overexpression promoted cell proliferation and invasion, while LSM1 knockdown exerted the opposite effects. Moreover, we discovered correlations between LSM1 expression and immune cell infiltration in GBM, specifically involving TFH cells, CD56bright cells, macrophages, and Th2 cells. Conclusions: The findings of this study demonstrate the upregulation of LSM1 in GBM and its contribution to tumor progression by enhancing cell proliferation, invasion, and influencing immune cell infiltration. Our research sheds light on the potential oncogenic role of LSM1 in GBM and suggests its viability as a therapeutic target for this aggressive brain tumor.

Identifiers

PMID37954131
PMCPMC10635750
OpenAlexW4388209832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.